Elan to push ahead with Alzheimer's drug trial

Athlone-based pharmaceutical company Elan and Wyeth Pharmaceuticals are to initiate a phase three clinical programme of a drug for the treatment of patients with mild to moderate Alzheimer's Disease.

The phase three trial of Bapineuzumab will start in the second half of this year, subject to regulatory approval.